These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25988965)

  • 1. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 6. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide.
    Lacy MQ; McCurdy AR
    Blood; 2013 Oct; 122(14):2305-9. PubMed ID: 23974193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide: when expectations are understated.
    Di Raimondo F; Conticello C
    Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety of pomalidomide for the treatment of multiple myeloma.
    Jones JR; Pawlyn C; Davies FE; Morgan GJ
    Expert Opin Drug Saf; 2016; 15(4):535-47. PubMed ID: 26913560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
    Watanabe N; Kitahara H; Iwao N; Ohta Y; Koike M; Komatsu N
    Geriatr Gerontol Int; 2018 Jun; 18(6):977-979. PubMed ID: 29924492
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetics of pomalidomide.
    Li Y; Xu Y; Liu L; Wang X; Palmisano M; Zhou S
    J Clin Pharmacol; 2015 May; 55(5):563-72. PubMed ID: 25556560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 17. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 18. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide: first global approval.
    Elkinson S; McCormack PL
    Drugs; 2013 May; 73(6):595-604. PubMed ID: 23572409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
    Srkalovic G; Hussein M
    Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.